ERCC1 and ERCC2 polymorphisms predict the clinical outcomes of oxaliplatin-based adjuvant chemotherapy in colorectal cancer

作者：Shi Lei; Wang Ran; Wu Wen ming; Huang Yi fei

来源：African Journal of Pharmacy and Pharmacology, 2012, 6(32): 2429-2432.

DOI：10.5897/AJPP12.862

• Excision repair cross-complementation group 1 (ERCC1 rs11615C &gt
• T)
• excision repair cross-complementation group 2 (ERCC2 rs13181T &gt
• G)
• colorectal cancer
• chemotherapy

Platinum agents have shown to be effective in the treatment of colorectal cancer. We conducted a prospective study to investigate the effect of excision repair cross-complementation group 1 (ERCC1 rs11615C>T) and Excision repair cross-complementation group 2 (ERCC2 rs13181T>G) on the efficacy of oxaliplatin-based adjuvant chemotherapy in colorectal cancer patients. A total of 335 cases newly diagnosed by histologically procedure as primary advanced colorectal cancer were collected. The genotypes of ERCC1 rs11615C>T and ERCC2 rs13181T>G genotyping was conducted with TaqMan Gene Expression assays using the ABI PRISM (R) 7900HT Sequence Detection System. All the patients were followed up until death or the end of November, 2011. The median follow-up period was 34.6 months, and 195 patients died during the follow-up. Compared with carrying ERCC1 T/T genotype, patients with a homozygous ERCC1 C/C genotype had a longer survival time. Similarly, the ERCC2 G/G genotype carriers had a lower risk of death from colorectal cancer compared with T/T genotype carriers. Our study suggested that the ERCC1 rs11615C>T and ERCC2 rs13181T>G single-nucleotide polymorphisms (SNPs) could be a predictive marker for the prognosis of colorectal cancer. Further studies are needed to validate the results of our study in Chinese population.

• 出版日期2012-8